Latest Breaking News On - Leukocyte adhesion deficiency i - Page 7 : comparemela.com

Rocket Pharmaceuticals (RCKT) Granted FDA Fast Track and Orphan Drug Designations for RP-A601

Rocket Pharmaceuticals (RCKT) Granted FDA Fast Track and Orphan Drug Designations for RP-A601
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Kevin giordanoRocket pharmaceuticals incDrug administrationRocket pharmaceuticalsFast trackOrphan drugInvestigational new drugRolling reviewBiologic license applicationArrhythmogenic cardiomyopathyFanconi anemiaLeukocyte adhesion deficiency iPyruvate kinase deficiencyDanon diseasePrivate securities litigation reform actAnnual report

Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease

Rocket Pharmaceuticals, Inc. , a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today. | May 31, 2023

Kinnari patelRocket pharmaceuticals incEuropean medicines agencyYork heart associationRocket pharmaceuticalsPriority medicinesDanon diseaseRegenerative medicine advanced therapyFast trackOrphan drugRare pediatricChief operating officerEuropean regulatoryNew york heart associationKansas city cardiomyopathyFanconi anemia

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD)

Rocket Pharmaceuticals, Inc. , a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today. | May 23, 2023

United statesInvestigaciones energKinnari patelEnfermedades rarasMedioambientalesy tecnolRocket pharmaceuticals incDrug administrationMeeting of the american society geneRocket pharmaceuticalsRegenerative medicine advanced therapyPyruvate kinase deficiencyChief operating officerCentury cures actBreakthrough therapyFast trackOrphan drug

Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Robust and sustained efficacy in both adult PKD patients up to 30 months post-RP-L301; first pediatric patient results suggest efficacy similar to adult cohort with initial greater than five-point. | May 19, 2023

United statesState of californiaInvestigaciones energLos angelesEnfermedades rarasKaplan meierMedioambientalesy tecnolJonathan schwartzRocket pharmaceuticals incMeeting of the american society geneCalifornia institute for regenerative medicine grant numberRocket pharmaceuticalsPyruvate kinase deficiencyFanconi anemiaSevere leukocyte adhesion deficiency iDanon disease

Rocket Pharmaceuticals (RCKT) Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs

Rocket Pharmaceuticals (RCKT) Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesState of californiaInvestigaciones energKaplan meierJonathan schwartzLos angelesKevin giordanoEnfermedades rarasMedioambientalesy tecnolDrug administrationCalifornia institute for regenerative medicine grant numberRocket pharmaceuticals incMeeting of the american society geneWall streetPyruvate kinase deficiencyFanconi anemia